Abstract
Background
The aim of this study was to evaluate the efficacy of somatostatin, ulinastatin and
Salvia miltiorrhiza for treatment of severe acute pancreatitis.
Methods
Three hundred six patients with severe acute pancreatitis were divided randomly into
5 groups: basic treatment, somatostatin, somatostatin + ulinastatin, somatostatin
+ S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza. Amount of time for resolution of abdominal pain/distention, recovery to normal heart
and respiratory rates, amylase and blood glucose levels, Acute Physiology and Chronic
Health Evaluation II scores, and levels of tumor necrosis factor-α, interleukin (IL)-6,
and IL-10 were analyzed and recorded for all 5 subgroups.
Results
Tumor necrosis factor-α and IL-6 levels on the fourth and seventh days, and Acute
Physiology and Chronic Health Evaluation II scores on the seventh day after treatment
showed significant decrease in the somatostatin, somatostatin + ulinastatin, somatostatin
+ S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza subgroups compared with the basic treatment subgroup. IL-10 levels on the fourth
and seventh days were significantly improved in the somatostatin + ulinastatin, somatostatin
+ S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza subgroups compared with the basic treatment subgroup. The incidences of pancreatic
sepsis, multiple organ dysfunction syndrome and mortality were lower in the somatostatin,
somatostatin + ulinastatin, somatostatin + S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza subgroups compared with the basic treatment subgroup.
Conclusions
Somatostatin is effective for the treatment of acute pancreatitis and both ulinastatin
and S miltiorrhiza demonstrate improvement in therapeutic benefits.
Key Indexing Terms
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of the Medical SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
- Early severe acute pancreatitis: characteristics of a new subgroup.Pancreas. 2001; 22: 274-278
- Fulminant acute pancreatitis and infected necrosis: results of open management of the abdomen and “planned” reoperations.J Am Coll Surg. 1998; 187: 255-262
- Cytokines and organ failure in acute pancreatitis: inflammatory response in acute pancreatitis.Pancreas. 2012; 41: 271-277
- Inflammation and immunosuppression in severe acute pancreatitis.World J Gastroenterol. 2010; 16: 2867-2872
- A clinically based classification system for acute pancreatitis.Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993; 128 (3rd): 586-590
- Pancreatitis associated with pancreatic carcinoma. Preoperative diagnosis: role of CT imaging in detection and evaluation.Pancreatology. 2005; 5: 330-344
- New diagnostic criteria of acute pancreatitis.Hepatobiliary Pancreat Sci. 2010; 17: 24-36
- Differential roles of inflammatory cells in pancreatitis.J Gastroenterol Hepatol. 2012; 27: 47-51
- Intra-abdominal hypertension in patients with severe acute pancreatitis.Crit Care. 2005; 9: R452-7
- Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis.Br J Surg. 2006; 93: 738-744
- Clinical relevance of intra-abdominal hypertension in patients with severe acute pancreatitis.Pancreas. 2008; 36: 39-43
- Gene targeting demonstrates additive detrimental effects of interleukin 1 and tumor necrosis factor during pancreatitis.Gastroenterology. 1997; 113: 1741-1746
- Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody.Am J Surg. 1994; 167: 214-218
- Calcium channel blockade inhibits release of TNF alpha and improves survival in a rat model of acute pancreatitis.Pancreas. 1996; 13: 22-28
- Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis.Am J Gastroenterol. 1999; 94: 213-218
- Interleukin-10 therapy—review of a new approach.Pharmacol Rev. 2003; 55: 241-269
- Somatostatin and octreotide on the treatment of acute pancreatitis—basic and clinical studies for three decades.Curr Pharm Des. 2011; 17: 1594-1601
- Comparison of integrated Chinese and Western medicine with and without somatostatin supplement in the treatment of severe acute pancreatitis.World J Gastroenterol. 2005; 11: 1073-1076
- Inhibitory effects of somatostatin on tumor necrosis factor-alpha-induced interleukin-6 secretion in human pancreatic periacinar myofibroblasts.Int J Mol Med. 2002; 10: 89-93
- Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor’s New Clothes or Aladdin’s Magic Lamp?.Pancreas. 2010; 39: 1231-1237
- Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.J Gastroenterol. 2007; 42: 161-167
- Protective effects of ulinastatin on proliferation and cytokine release of splenocytes from rats with severe acute pancreatitis.Eur Surg Res. 2006; 38: 445-450
- Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis.Chin Med J (Engl). 2010; 23: 2600-2606
- Protective effects of Salvia miltiorrhiza on multiple organs of rats with obstructive jaundice.Mediators Inflamm. 2009; 2009: 602935
- Lipid-soluble extracts from Salvia miltiorrhiza inhibit production of LPS-induced inflammatory mediators via NF-κB modulation in RAW 264.7 cells and perform antiinflammatory effects in vivo. Phytother Res. 2012; 26: 1195-1204
Article info
Publication history
Accepted:
October 12,
2012
Received:
April 30,
2012
Footnotes
Disclosure: The authors have no direct relationship with any of the companies mentioned in this article, either by employment or by receiving research grants.
This study was supported by the National Natural Science Foundation of China (81071594) and the National Natural Science Foundation of Science and Technology Hall of Jiangxi Province, China (20091391308000).
Identification
Copyright
© 2013 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
